Studies of the pathogenesis of dengue hemorrhagic fever (DHF), a potentially life-threatening disease, have revealed the importance of initial high levels of virus replication. However, the possible involvement of virus during the transition from fever to defervescence, a critical stage in determining the severity of disease, has not been appreciated. Using quantitative reverse transcription-polymerase chain reaction, we examined the levels of plasma dengue viral load during both fever and defervescence periods in patients from a DEN-3 outbreak in southern Taiwan in 1998. Higher levels of plasma dengue viral RNA were found in DHF patients than in DF patients. During defervescence, while the level of plasma dengue viral RNA was undetectable in most DF patients, it remains high in all DHF patients. Using a modified immunoprecipitation assay, we demonstrated for the first time that the plasma dengue viruses persisting during defervescence were in the immune complexes for most DHF patients. These findings suggest that continued active viral replication or delay in the clearance of viremia contributes to the pathogenesis of DHF. Moreover, high levels of plasma dengue viral RNA during defervescence may serve as a disease marker for DHF.
INTRODUCTION
Among the 70 or so arthropod-borne flaviviruses, outbreaks of the four serotypes of dengue virus (DEN-1, DEN-2, DEN-3, and DEN-4) continue to be a major public health problem in tropical and subtropical areas (Monath, 1994; Innis, 1995; Gubler, 1998) . While most dengue virus infections develop as asymptomatic or mild, self-limited illness, in the form of dengue fever (DF), some patients may develop severe and potentially lifethreatening diseases, dengue hemorrhagic fever-dengue shock syndrome (DHF/DSS) (Innis, 1995; WHO, 1997; Gubler, 1998) . It has been estimated that approximately 100,000,000 dengue infections occur annually throughout the world (Halstead, 1988; Monath, 1994; Gubler, 1998) .
The initial clinical presentations of DF and DHF/DSS are similar, both including a sudden onset of fever and a variety of nonspecific symptoms and signs (Innis, 1995; WHO, 1997; Gubler, 1998) . It is at the time of defervescence that severe hemorrhage and circulatory failure occur in DHF/DSS patients. Without early diagnosis and prompt treatment, patients will die quickly (Innis, 1995; WHO, 1997; Gubler, 1998) .
Along with other valuable insights, two major hypotheses, the immune and the viral hypotheses, have been proposed regarding the pathogenesis of DHF/DSS (Innis, 1995; Gubler, 1998) . The immune hypothesis attempts to explain the epidemiological observations that individuals experiencing secondary infections with a heterologous dengue serotype had a significantly higher risk of developing DHF/DSS (Halstead, 1988; Burke et al., 1988; Thein et al., 1997) . Dengue viruses have been shown to replicate to higher titers in human monocytes in the presence of cross-reactive nonneutralizing antibodies in vitro (Halstead and O'Rourke, 1977; . The antibody-dependent enhancement (ADE) phenomenon is believed to augment viral replication in vivo by increasing the numbers of dengue-infected antigen-presenting cells. The increase results in profound activation of preexisting cross-reactive cytotoxic T-lymphocytes and the release of cytokines and cellular mediators, thus leading to subsequent immunopathological processes and DHF/DSS (Innis, 1995; Gubler, 1998; Green et al., 1999; Rothman and Ennis, 1999) . The viral hypothesis proposes that the severity of the disease is related to the strains of the viruses; some virus strains may have evolved to replicate faster and to higher levels with greater epidemic potential, thus causing more severe diseases (Rosen, 1977; Gubler et al., 1978; Leitmeyer et al., 1999) .
As suggested by both hypotheses, the outcome of disease severity correlates directly with the magnitude of viral replication. Investigations of various clinical, virological, and immunological parameters during the course of infection have revealed the contribution of initial high levels of virus replication to DHF/DSS (Vaughn et al., 1997 (Vaughn et al., , 2000 Murgue et al., 2000; Libraty et al., 2002) . However, the involvement of viruses in the later process, particularly during the transition from fever to defervescence that is a critical stage in determining the severity of diseases, has not been examined thoroughly. Previously, we established a convenient and sensitive quantitative competitive-reverse transcription-polymerase chain reaction (QC-RT-PCR) assay for quantification of dengue viruses . In this study, we investigated the levels of plasma dengue viral load during both fever and defervescence periods in patients from a DEN-3 outbreak in southern Taiwan in 1998. We report here that DHF patients continue to have high levels of plasma dengue viral RNA during defervescence and demonstrate that plasma dengue viruses persisting in the DHF patients during defervescence were in the immune complexes.
RESULTS

Study participants
The basic demographic, clinical, and virological information on the 20 DEN-3 patients, including 11 DF and 9 DHF, are summarized in Table 1 . The male-to-female ratio was 1. The ages of the participants ranged from 23 to 70 years. There were no statistical differences in gender, age, duration of fever, or sampling time between the DF and DHF groups (P ϭ 0.5, Fisher's exact two-tailed test, P ϭ 0.33, P ϭ 0.41, and P ϭ 0.82, Mann-Whitney test, respectively).
Quantification of plasma dengue RNA by RT-PCR
We first employed a QC-RT-PCR assay, modified from a previously established method , to investigate the levels of plasma dengue viral RNA. Figure  1 illustrates the results of QC-RT-PCR of two patients, ID 22 and ID 24. For ID 22, addition of increasing amounts of the competitor RNA, Ci40-RNA, to replicate reactions containing identical amounts of target RNA resulted in a gradual increase in the intensity of the 210-bp product and a gradual decrease in the intensity of the 170-bp product (Fig. 1B, left) . The point where the ratio of Cor. Int. 210 to Int. 170 equals 1 (molar equivalence) represents the amount of target RNA, which was determined to be 998 copies, corresponding to 594,000 copies of RNA per milliliter plasma. For ID 24, the amount of RNA was determined to be 2206 copies per reaction, corresponding to 1,310,000 copies of RNA per milliliter plasma (Fig. 1C) . Of note was that for reactions near the equivalent points, there was a third band migrating slower than the 170-and 210-bp products (Fig. 1B , lanes of 100 to 5000 copies competitors, and Fig. 1C , lanes of 500 to 10,000 copies competitors). The slower migration pattern and the prominence of the bands seen only in reactions near the equivalent points suggest that these bands are heteroduplex complexes between the two differently sized products. Such heteroduplexes would not affect the accuracy of our quantification, since it was based on the relative amount of the product of the target to that of the competitor RNA, and both products will in principle be similarly affected by the formation of the heteroduplex complex (Piatak et al., 1993; Freeman et al., 1999; Wang et al., 2000) .
High levels of plasma dengue RNA persisting in DHF patients
The levels of plasma dengue RNA of the 20 patients thus determined range from less than 600 copies to 14,900,000 copies of RNA per milliliter plasma (Table 1) . There is no significant difference in the levels of plasma dengue RNA with regards to age, gender, or primary versus secondary antibody response (P ϭ 0.93, ANOVA, P ϭ 0.39, and P ϭ 0.53, Mann-Whitney test, respectively). Compared with those in the DF patients, the levels of dengue RNA in the DHF patients were significantly higher ( Fig. 2A , P ϭ 0.025, Mann-Whitney test). We next analyzed the samples collected during the fever and defervescence periods separately. When only febrile patients were compared, the levels of plasma dengue RNA in the DHF group, ID18 to ID21 (geometric mean: 6.19 log copies/ml), were higher than those in the DF group, ID2 to ID9 (geometric mean: 5.08 log copies/ml), though this has not reached statistical significance (P ϭ 0.48, Mann-Whitney test) (Fig. 2B ). During defervescence, all DF patients except one have dengue RNA below the detection limit. In contrast, all DHF patients retain high levels of dengue RNA (geometric mean: 5.64 log copies/ml) (Fig. 2C) . The difference was highly significant (P ϭ 0.008, Mann-Whitney test).
Analysis of sequential plasma samples
The differences in plasma dengue RNA observed between DF and DHF patients suggest that there are different patterns of viremia during the transition from fever to defervescence. To investigate such possibility, we examined sequential plasma samples from six patients, three DHF and three DF. One of the DHF patients was ID 18, from whom the first sample was taken on day 3 and the second on day 9. The other two DHF patients (ID30 and ID31, both DEN-2) and the three DF patients (ID 27 and ID 28, and ID29, were identified between 1999 and 2001. The clinical course and plasma dengue RNA level are shown in Fig. 3 . For all three DF patients, the levels of dengue RNA declined to the level below detection when the fever subsided (Figs. 3A-3C ). In contrast, dengue RNA remains in plasma for up to 6 days after defervescence in DHF patients (Fig. 3D-3F ). These results, though based on a small sample size examined, are in agreement with the cross-sectional observations and indicate that DF and DHF patients have different patterns of viremia during the course of infection. Moreover, these findings suggest that high levels of plasma dengue RNA persisting after defervescence may serve as a marker for DHF.
Dengue viruses in the immune complexes
It has been reported that anti-dengue IgM antibody developed within 5 days of onset and were detectable in more than 90% of the patients from day 6 to day 10 (Gubler, 1998; Vaughn et al., 1999) . In this study, all five defervescence samples from DHF patients (ID22 to 26) had detectable anti-dengue antibodies (Table 1 and data not shown). To investigate whether the dengue viruses persisting at defervescence in the DHF patients were contained in the immune complexes, we employed a modified immunoprecipitation assay. In the reconstitution experiment, equal amounts of a DEN-2 virus were preincubated with or without anti-dengue mAb before incubation with immobilized protein G. Dengue viral RNA isolated from the unbound and the bound fractions were subjected to quantitative RT-PCR. A band of the expected size of 170 bp was detected in the bound fraction of the reaction containing a DEN-2 specific anti-envelope mAb, 3H5, but not in those containing no antibody or containing 5D4, a DEN-3-specific anti-NS1 mAb (Fig. 4A) . The proportion of bound fraction by 3H5 was calculated to be 33.3%.
We next incubated with immobilized protein G the plasma from five DHF patients (ID 22 to 26) at defervescence as well as plasma from five DF patients and examined the amounts of dengue RNA in the unbound and the bound fractions. With the exception of ID 25, considerable amounts of dengue RNA, corresponding to 7.2 to 42.5% of the total, were detected in the bound fractions of the defervescence plasma of the other four DHF patients (Fig. 4B) . In contrast, no dengue RNA was found in the bound fractions of the control DEN-3 H87 virus or that of the plasma from DF patients, who have either detectable anti-dengue antibodies (ID4, 8, 9, and 17) or have not yet developed antidengue antibody (ID6) (Fig. 4B and data not shown) .
DISCUSSION
In this study, we used the quantitative RT-PCR method, which is more sensitive and convenient than virus isolation, to investigate the relationship between plasma dengue viral load and disease severity during the course of infection (Piatak et al., 1993; Freeman et al., 1999; Murgue et al., 2000; Wang et al., 2000; Sudiro et al., 2001) . Consistent with the outcome predicted by both immune and viral theories, higher levels of dengue RNA were seen in DHF patients than in DF patients, when comparing all acute plasma samples together ( Fig. 2A) (Rosen, 1977; Halstead, 1988; Innis, 1995; Gubler, 1998; Thein et al., 1997) . Uniquely, we found that DHF patients, in contrast to DF patients, continue to have high levels of plasma dengue viral RNA during defervescence, a critical stage in determining the severity of disease. Moreover, we demonstrated for the first time that the plasma dengue viruses persisting during defervescence were in the immune complexes for most DHF patients. These findings illustrate the importance of both viral and host factors during the transition from fever to defervescence and would provide new insights into our understanding of the pathogenesis of dengue (Innis, 1995; Gubler, 1998; Thein et al., 1997) .
Using the PanBio IgM and IgG capture ELISA and the HI tests, 10 primary infections were found among the 20 patients in this study (Table 1 ). The possibility of Japanese encephalitis virus (JEV) infection was excluded, since all cases were negative for the JEV IgM-ELISA (Shu et al., 2000) . Moreover, dengue viral signals were detected by the two-round RT-PCR assay and confirmed by DNA sequencing in all cases (data not shown). The observation of a high proportion of primary infection is in agreement with a recent report of the same outbreak by another medical center in Taiwan (Huang et al., 2001) . This is probably due to the absence of dengue outbreak since 1943 in the central district of Tainan city, in which most cases of this study were found . A strong association of secondary infection with older age (older than 55 years old) through stratification analysis further supports this interpretation (Fisher's exact test, P ϭ 0.005). These findings suggest that the epidemiology of dengue in Taiwan is different from that in Southeast Asia, where predominantly secondary infections were reported by pediatric studies (Gubler et al., 1981; Vaughn et al., 1997 Vaughn et al., , 2000 . With the small sample size studied here, secondary infection was not found to be associated with DHF (Table 1 , 5 secondary infections of 9 DHF cases versus 5 secondary infections of 11 DF cases, P ϭ 0.5, Fisher's exact two-tailed test).
The most interesting observation of this study was that while most DF patients had undetectable plasma dengue RNA during defervescence, all DHF patients continued to have high levels (Fig. 2C ). This striking difference could not be attributed to earlier sampling for the DHF
FIG. 4. Detection of dengue viruses in the immune complexes. (A)
RT-PCR products of the RNA derived from the bound (B) and unbound (U) fractions of a DEN-2 virus (left), and of the standard RNA (C-RNA) from 10 to 10,000 copies (right). Lanes: total, incubated neither with antibody nor protein G; mock, no RNA added; no Ab, not preincubated with antibody; 5D4, a DEN-3 specific anti-NS1 mAb; 3H5, a DEN-2 specific anti-envelope mAb; m, molecular size marker. (B) RT-PCR products of RNA derived from the B and U fractions of dengue viruses in plasma of DF and DHF patients, as well as in culture supernatants of a DEN-3 virus, H87. m, molecular size marker.
group than for the DF group, since there is no significant difference in the sampling time after fever between the two groups (Table 1, P ϭ 1.0, Mann-Whitney test). This observation was further confirmed by analysis of sequential samples (Fig. 3) . Previous studies reported that the magnitude of viremia, as measured by virus isolation, did not vary significantly with the severity of disease (Gubler et al., 1979 (Gubler et al., , 1981 . Vaughn et al. reported recently that plasma viremia cleared up more quickly and were therefore lower in DHF patients than in DF patients at defervescence (Vaughn et al., 2000) . Patients in Vaughn's study were children (18 months to 14 years old), whereas patients in our study were adults (23 to 70 years old). Differences in host immune response and disease presentations between children and adults have been observed in other viral infections, such as lymphocytic choriomeningitis virus and human and simian immunodeficiency viruses (Oldstone, 1987; Falloon et al., 1989; Baba et al., 1995) . Whether age may account for the different duration and pattern of dengue viremia with regards to disease severity remains to be investigated. In Vaughn's study, viremia was determined through virus isolation, which detects intact virions, whereas viremia was determined by the levels of RNA in our study. It is worth noting that virus isolation could potentially encounter interference from the presence of antibodies or immune complexes in the plasma, particularly in the cases of secondary infection (Ruangjirachuporon et al., 1979; Scott et al., 1980; Gubler et al., 1981; Vaughn et al., 1997) . Since more than 90% of the DHF patients were cases of secondary infection (Vaughn et al., 2000) , large amounts of antibodies and/or immune complexes near defervescence may result in lower efficiency of virus isolation and lower viremia. Consistent with this interpretation were two recent studies showing that higher viremia (as determined by RT-PCR methods) in DHF patients than in DF patients persists up to defervescence, though at a level close to the limit of detection (Murgue et al., 2000; Libraty et al., 2002) . Another study using QC-RT-PCR methods revealed that while many patients had plasma dengue RNA levels below detection by defervescence, approximately one-third retained detectable dengue RNA (Sudiro et al., 2001) . It is likely that most of this one-third are DHF patients.
Our findings that plasma dengue RNA persists during defervescence in all DHF patients and that considerable amounts of them are in the immune complexes would have important implications to our understanding of the pathogenesis of dengue. Since larger numbers of infected cells in DHF than in DF patients, as evidenced by the levels of viremia, are assumed to have occurred during the fever period, it is possible that residual RNA continues to be released after defervescence in DHF patients but not in DF patients. Alternatively, active viral replication continues in DHF patients during defervescence. This was supported by the observations that DEN-3 virus can be isolated at later time points of infection from DHF patients, including ID22 and ID25 at day 8 (data not shown). Third, a large amount of defective viruses are produced and therefore not detected by virus isolation. RT-PCR with another primer pair targeting the NS5 region was used to test our samples and revealed essentially the same finding, i.e., that dengue viral RNA were present in plasma in all DHF patients, but not in DF patients, during defervescence (data not shown). This suggests that defective viruses containing large genomic deletions are unlikely to account for the viruses seen in the DHF patients.
Another possibility is that the clearance of plasma dengue viruses during defervescence is not as effective in DHF patients as in DF patients, thus leading to subsequent immunopathological processes. In this regard, we found that dengue viruses were in the immune complexes from four of five DHF patients at defervescence, but not in such from four DF patients, who had detectable anti-dengue antibodies (Fig. 4B and data not shown) . This is consistent with a previous report that circulating immune complexes were found in 80% of DHF patients, especially at the subsidence of fever (Ruangjirachuporon et al., 1979) . Of note was that the dengue virus-containing immune complex observed in our DHF patients could not be attributed to secondary antibody response, since it was seen in both primary and secondary infections ( Fig.  4B and Table 1 ). Several immune activation markers and cytokines have been reported to be associated with DHF/DSS (Gubler, 1998; Green et al., 1999; Rothman and Ennis, 1999) . Quantitative differences in host immune responses and the timing of type 1 cytokine responses were recently shown to have differing influences on the severity of disease manifestations during secondary DEN-3 virus infections (Libraty et al., 2002) . Therefore, to address the roles of the immune complexes in the pathogenesis of DHF/DSS or in the clearance of viremia would require future studies of the dynamic changes of the virus-containing immune complex, and plasma viral load, monitored by both viral RNA detection and virus isolation, together with other immunological parameters, including antibody titers and T cell immune responses during the course of infection.
In summary, our findings suggest that high levels of plasma dengue RNA during defervescence serve as a disease marker of DHF. Based on our analysis, plasma dengue RNA levels higher than 10 4 copies per milliliter at day 2 of defervescence are able to distinguish DHF from DF patients (Fig. 2C) . Nonetheless, due to the dynamic nature of viremia in dengue infection, further analysis of more cases at comparable and multiple time points during the transition from fever to defervescence is required to define a cutoff value as the marker or predictor for the development of DHF.
MATERIALS AND METHODS
Study participants
The diagnoses of DF and DHF followed the WHO clinical definition (WHO, 1997). Detection of dengue genomic sequences in plasma by a previously described two-round RT-PCR assay, which included RT-PCR and a second round PCR, was the laboratory criteria of confirmation for all cases (Lanciotti et al., 1992; WHO, 1997) . Between November and mid-December 1998, during an outbreak in southern Taiwan, there were 20 dengue patients at three hospitals (Chi-Mei Foundation Medical Center, Kuo General Hospital, and Sin-Lau Christian Hospital) confirmed at our laboratory . The day of onset of fever (oral temperature Ն38°C) is defined as day 1 of illness (d1). Defervescence is the period that oral temperature is below 38°C without further elevation, and the first day of defervescence (ϩ1) is thus defined. Acute blood samples were collected in EDTA-containing tubes between day 2 and day 8 of illness. Plasma was prepared within 6 h of collection and stored at Ϫ80°C until use . The patients were closely observed during hospitalization and monitored with routine laboratory tests. After careful review of the charts by infectious disease physicians, the severity of disease was assessed by the WHO grading system (WHO, 1997; Murgue et al., 2000; Vaughn et al., 2000) . The serotype of the 20 dengue patients was determined to be DEN-3 using the two-round RT-PCR assay, which can distinguish the four dengue serotypes by the size of the products (Lanciotti et al., 1992) .
To determine primary or secondary dengue virus infection, two methods were used in testing the convalescent sera. One is the commercial IgM and IgG capture ELISA (PanBio Dengue Duo, Brisbane, Australia), which contained stabilized dengue antigens (DEN-1 to DEN-4) in one plate and anti-human IgM or anti-human IgG in another plate . The ratio of the absorbance at 450 nm of the patients' sera (1:100 dilution) to that of the reference sera provided (cutoff calibrators, CO) were determined, and a ratio Ն1 was defined as positive. An IgM/CO Ն 1 and IgG/CO Ͻ 3 are considered primary infection, and an IgG/CO Ն 3 is considered secondary infection as described previously . The other method is the traditional hemagglutination inhibition (HI) test, in which primary (HI titer Յ 1280) or secondary (HI titer Ͼ 1280) infection was classified according to the WHO definition (WHO, 1997) . Both methods showed consistent results. In addition, all serum samples were tested with a previously described JEV-NS1 IgM ELISA to exclude JEV infection (Shu et al., 2000) , and all were negative.
Sequential samples, collected from 1999 to 2001, taken at two to three time points, from three DF patients and two DHF patients at the Kaoshiung Veterans General Hospital and the Yuan General Hospital in southern Taiwan are also included in the analysis.
Isolation of viral RNA from plasma
Dengue viral RNA was isolated from plasma using the QIAamp viral RNA mini kit (Qiagen, Germany) as described previously .
RT-PCR primers
The primer pair, d3C14A and d3C69B, was modified from a previously described primer pair, which can detect all four dengue serotypes but not other flaviviruses . The sequence of d3C14A was 5Ј-AATATGCTGAAACGCGTGAGAAACCG-3Ј (genome positions 134 to 159 of the DEN-3 H87 strain) (Osatomi and Sumiyoshi, 1990) , and the sequence of d3C69B was 5Ј-CCCATCTAGCCAAGACTCCTGCTGT-3Ј (positions 278 to 302 of the H87 strain). They were designed to amplify a 170-bp product for dengue RNA or a 210-bp product for competitor RNA in the capsid (C) region.
Generation of the constructs and RNA
C/pCRII-TOPO was a plasmid containing the entire C region and the N-terminal six amino acids of the precursor membrane (PrM) region of DEN-3 strain H-87 in the vector pCRII-TOPO (Invitrogen, San Diego, CA). The RNA of the C region, C-RNA, was generated by T7 in vitro transcription (Promega, Madison, WI) of the linealized C/pCRII-TOPO, purified, and quantified . The competitor construct, Ci40/pCRII-TOPO, was modified from C/pCRII-TOPO by digestion with the restriction enzyme, HincII, followed by filling both 3Ј recessed ends and inserting a 40-bp adaptor (Fig. 1A) . The competitor RNA, Ci40-RNA, was generated from the linealized Ci40/pCRII-TOPO and quantified .
Quantitative RT-PCR
To obtain adequate quantification, RNA eluates from some plasma samples were diluted 10-to 10,000-fold. For the QC-RT-PCR assay, equal amounts (6 l) of the diluted RNA eluates were mixed with increasing copy numbers of Ci40-RNA and were subjected to RT-PCR. For the noncompetitive quantitative RT-PCR, equal amounts (6 l) of the RNA eluates and increasing copy numbers of the C-RNA were subjected to RT-PCR simultaneously under the conditions described previously . The RT-PCR products were electrophoresed through 2% agarose gel, stained, and measured. RT-PCR products with the predicted size of 170 bp were seen in most samples, but not in reactions containing no RNA, or RNA from healthy donors, or when the RT step was omitted.
For QC-RT-PCR, the ratios of the corrected intensity of 210 bp (by a factor of 210/170) to that of 170 bp (Cor. Int. 210/Int. 170) were plotted against the copy number of the competitor RNA (both in log scale), with the regression line and coefficient of determination, R 2 , determined. The copy numbers of dengue RNA per reaction thus determined were used to calculate the RNA copies per milliliter plasma. The sensitivity was 10 copies RNA per reaction as reported previously , corresponding to 600 copies RNA per milliliter plasma. For noncompetitive RT-PCR, the intensity of the 170-bp products was plotted against the copy number of C-RNA (both in log scale) to generate a standard curve. The copy numbers of RNA per milliliter plasma were determined.
Detection of dengue viruses in the immune complexes
Two murine antidengue monoclonal antibodies (mAbs), 3H5 (a DEN-2 specific anti-envelope mAb) and 5D4 (a DEN-3 specific anti-NS1 mAb), were derived from hybridomas, 3H5-1 and 5D4-11, respectively (American Type Culture Collection, Rockville, MD) Henchal et al., 1982) . In the reconstitution experiment, equal amounts of DEN-2 New Guinea virus were incubated with or without antibody, at 4°C for 4 h, followed by incubation with immobilized protein G, which can bind human IgM and IgG, at 4°C for 4 h (Pierce, Rockford, IL). The unbound fractions were removed after centrifugation for 1 min. The immune complexes were washed six times with 0.5 ml binding buffer and subsequently eluted with the elution buffer to obtain the bound fractions (Pierce). Of note was that the amounts of dengue RNA derived from the unbound plus the bound fractions were comparable to the total dengue RNA at initial input, indicating that negligible amounts were lost during washing (Fig. 4A ). For detection of dengue viruses in the circulating immune complexes, aliquots of plasma and of culture supernatants of a DEN-3 virus, H87, were incubated with protein G at 4°C for 4 h, followed by washing and elution. Dengue viral RNA, isolated from the unbound and bound fractions, was subjected to noncompetitive quantitative RT-PCR. The proportion of bound RNA was calculated by the ratio of bound/bound ϩ unbound.
Statistical analysis
A nonparametric statistical method, the Mann-Whitney test in the software SPSS base 8.0 (SPSS Inc., Chicago, IL), was employed to compare age, fever duration, sampling time, and levels of viral RNA between groups. Fisher's exact test was used to compare the difference in gender and primary versus secondary infection between DF and DHF patients.
